

References

- **Abdo AA, Bain VG, Kichian K, et al., (2001):** Evolution of autoimmune hepatitis to primary sclerosing cholangitis: a sequential syndrome *Hepatology* 2002;36:1393-139
- **Abd E.L. Kader J. (2001):** School performance in children with liver disease. MSC. Thesis in pediatrics Benha faculty of Medicine. 62-63.
- **Acharya JN, Pacheco VH. (2008):** Neurologic complications of hepatitis C. 4: *Neurologist*. May;i4(3):151-6.
- **Adair D, Wilkinson J, Scheck A and et al., (2004):** Differential display and micro-array analysis show differentially expressed genes in central nervous system in HCV infected patients and laser capture microscopy points to brain microglia as cells harboring HCV.) *Hepatology* 40:433A
- **Adler M, Frotscher B, Thiry p and Gustot T. (1994):** High sero-prevalence of hepatitis C virus infection among risk groups in Egypt. *Am. J.Trop.Med.Hyg.*; 51 (5): 563-547
- **Adler M, Frotscher B, Thiry P and Gustot T (2004):** Non invasive markers of liver fibrosis in hepatitis C. *Aeta Gastroenterol Belg*. 67(3):278-81.
- **Afdhal NH and Nunes, D. (2004):** Evaluation of liver fibrosis: a concise review. *Am. J. Gastroenterol*. 2004. 99:1160-1174. View this article via: PubMed CrossRef

- **Agarwal, DP. (2001):**Genetic polymorphisms of alcohol metabolizing enzymes. *Pathol. Biol.* 49:703- 709. View this article via: PubMed CrossRef
- **Akhan O, Karaosmaaoglu AD and Ergen B. (2007):** Imaging findings in congenital hepatic fibrosis. *Eur J Radiol*;61(1):18-24
- **Akpolat N, Yahsi S, Godekmerdan A, et al., (2005):** Relationship between serum cytokine levels and histopathological changes of liver in patients with hepatitis B. *World J Gastroenterol*; 11 : 3260-3263. Links
- **Albanis E and Friedman, SL. (2001):** Hepatic fibrosis. Pathogenesis and principles of therapy. *Clin. Liver Dis.* 5:315-334, v-vi. View this article via: PubMed CrossRef
- **Albertino F, Gatta A, Amodio P, et al., (2001):** Nutritional and survival in patients with liver cirrhosis. *Nutrition.*; 17:445-450.
- **Aldana, H, Green, RM and Whittington, PF. (2004):** Upregulation of osteopontin expression is involved in the development of nonalcoholic steatohepatitis in a dietary murine model. *Am. J. Physiol. Gastrointest. Liver Physiol.* 287:G264-G273. View this article via:
- **Alvarez F, Berg PA, Bianchi FB, et al., (1999):** International Autoimmune Hepatitis Group Report: reviewof criteria for diagnosis of autoimmune hepatitis. *J Hepatol* 31:929- 938.

- **Anthony J. (2007):** Metabolic improvement by GH and IGF in liver disease AW Marrow Gastroenterology and liver centre Alferd Hospital- Univeristy Sydney – Austeralia (94,95).
- **Arthur MJ. (2000):** Metalloproteinases and their inhibitors in liver fibrosis. Am. J. Physiol. Gastrointest. Liver Physiol. 2000. 279:G245-G249. View this article via: PubMed
- **Arthur MJ. (2002):** Reversibility of liver fibrosis and cirrhosis following treatment for hepatitis C. Gastroenterology. 122:1525-1528. View this article via: PubMed CrossRef
- **Attallah AM, Zahran F, Ismail H and et al., (2007):** Immunochemical identification and detection of serum fibronectin in liver fibrosis in Patients with chronic hepatitis C. J Immunoassay Immunochem. 28(4):331-42.
- **Balisteri WF. (2000):** Pediatric hepatology. A half century of progress. Clin Liver Dis., 4: 191-210
- **Baroni G. Ridolfi F, Sario A,et al (1999):** Insulin and IGF1 stimulate proliferation of type 1 collagen accumulation by human hepatic stellate cells:differential effects on signal transduction pathways.Hepatology vol 29 .6. 1743:
- **Bataller, R and Brenner, DA. (2001):** Hepatic stellate cells as a target for the treatment of liver fibrosis. Semin. Liver Dis. 21:437-451. View this article via: PubMed CrossRef.

- **Bataller R, North KE, and Brenner DA. (2003):** Genetic polymorphisms and the progression of liver fibrosis: a critical appraisal. *Hepatology*. 37:493-503. View this article via: PubMed CrossRef.
- **Bataller R and Brenner DA (2005):** Liver fibrosis. *J Clin Invest*; 115: 209- 18.
- **Bedossa P and Poynard T (1996):** An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. *Hepatology*, 24: 289-293.
- **Bedossa P, Dargere D, and Paradis V. (2003):** Sampling variability of liver fibrosis in chronic hepatitis C *Hepatology*; 38: 1449-57.
- **Beinker NM and Pooley S. (2008):** Transforming growth factor beta and hepatocyte transdifferentiation in liver fibrogenesis. *J. Gastroenterol hepatol* 23 suppl S 122-7.
- **Bellomo-Brandao MA, Costa-Pinto EAL, De Tommaso AMA, et al., (2006):** Clinical and biochemical features of autoimmune hepatitis in 36 pediatric patients. *Arq Gastroenterol*.;43: 45-49.
- **Benyon, RC and Iredale, JP. (2000):** Is liver fibrosis reversible? *Gut*. 46:443-446. View this article via: PubMed CrossRef

- **Bergquist A, Ekbom A, Olsson R, et al., (2002):** Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. . J Hepatol :36:321-327.
- **Bianchi G, Loguercio C, Sgarbi D, et al., (2000):** Reduced quality of life in patients with chronic hepatitis C: effects of interferon treatment. Dig Liver Dis 2000;32:398-405.
- **Bianchi G, Loguercio C, Sgarbi D and et al., (2003):**Reduced quality of life of patients with hepatocellular carcinoma. Dig Liver Dis 35:46-54.
- **Bianchi G, Marchesint G and Niclonio F. (2005):** Psychological status and depression in patient with liver cirrhosis Dig liver disease : 2005 Aug 37 (8); 584-5.
- **Birch NC, Radio S, Horslen S.(2003):** Metastatic hepatocellular carcinoma in a patient with Niemann- Pick disease, type C.J Pediatr Gastroenterol Nutr; 37:624-62
- **Bissell DM, Roulot D and George J. (2001):**Transforming growth factor β and the liver. Hepatology; 34: 43. 859-67. 29.
- **Bittmann S (2005):** Surgical experience in children with biliary Artesia treated with porto enterostomy. Curr Surg; 62(4): 439-443.
- **Blume AW. Schmaling KB and Alan Marlat G.(2001):** Motivating drinking behavior change. Depressive symptoms may not be noxious. Addict Behav:26:267-72.

- **Boberg KM, Spurkland A, Rocca G, et al., (2001):** The HLA-DRs, DQ2 heterozygous genotype is associated with an accelerated progression of primary sclerosing cholangitis. *Scand J Gastroenterol*; 36:886-890.
- **Boberg KM. (2002):** Prevalence and epidemiology of autoimmune hepatitis. *Clin Liver Dis* 56:347-359.
- **Boeker RH, Haberkorn CI, Michels D and et al.,(2002):** Diagnostic potential of circulating TIMP-1 and MMP-2 as markers of liver fibrosis in patients with chronic hepatitis C. *Clin Chim Acta*; 316: 71-81.
- **Bonacini M, Hadi G, Govindarajan S and et al., (1997):** Utility of a discriminant score for diagnosing advanced fibrosis or cirrhosis in patients with chronic hepatitis C virus infection. *Am J. Gastroenterol*; 92(8): 1302-4.
- **Boya P, et al., (2001):** Nuclear factor-kappa B in the liver of patients with chronic hepatitis C: decreased expression is associated with enhanced fibrosis progression. *Hepatology*. 34:1041-1048. View this article via: PubMed CrossRef
- **Brancatelli G, Federle MP and Vilgrain V. (2005):** Fibropolycystic liver disease: CT and MR imaging findings. *Radioeraphics*; 25(3):659-70.
- **Breitkopf K, Hass S, Weerciniske E et al. (2005):** Anti TGF beta strategies for Treatment of chronic liver diseases. *Alchol clin Exp Res* 29(11)121s-131s

- **Breitkopf K, Lahme B, Tag CG and Gressner AM. (2001):** Expression and matrix deposition of latent transforming growth factor beta binding proteins in normal and fibrotic rat liver and trans-differentiating hepatic stellate cells in culture. *Hepatology*; 33:387-396.
- **Brewer GJ, Johnson VD, Dick RD, et al., (2005):** Treatment of Wilson's disease with zinc. XVII: Treatment during pregnancy. *Hepatology*;31:364-370.
- **Burak KW, Urbanski SJ and Swain MG.(2001):** A case of coexisting primary biliary cirrhosis and primary sclerosing cholangitis: a new overlap of autoimmune liver diseases. *Digest Dis Sci* :46:2043-2047.
- **Burra P, Patriza J and German L .(2010):** sexual dysfunction in chronic liver diseases: is liver transplantation an effective cure. *Transplantation* vol 89-1425-1425.
- **Callewaert, N, et al., (2004):**Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics. *Nat. Med.* 2004.10:429-434. View this article via: PubMed CrossRef
- **Canbay A, Friedman S. and Gores GJ. (2004):** Apoptosis: the nexus of liver injury and fibrosis. *Hepatology.* 39:273-278.View this article via: PubMed CrossRef
- **Caregaro L, Alberino F, Amodio P, et al., (2004):**Evaluation of liver fibrosis A concise Review. *Am J Gastroentrol* 99:1160-74.

- **Carreiro G. Villela-Nogueira CA, Coelho HS, et al., (2007):** Orthotopic liver transplantation in glucose-6-phosphatase deficiency Von Gierk disease with multiple hepatic adenomas and concomitant focal nodular hyperplasia. *J Pediatr Endocrinol Metab*;20:545-549.
- **Carrell RW and Lomas DA. (2002):** Alpha 1-antitrypsin deficiency -a model for conformational diseases. *N Engl J Med* 346:45-53.
- **Castilla-Cortazar et al, (2004):** Blood testis barrier is altered from early stages of cirrhosis: the effect of IGF1. *World J Gastroenterol*,10(17)2529-2534
- **Castera L, Constant A and Bernrd PH. (2006):** psycological impact of chronic Hepatitis C. comparsson with other life events and chronic diseases. *World J Gosteroentrol* 14; 12 (18) 1650.
- **Castera L, Hartmann DJ, Chapel F and et al., (2000):** Serum laminin and type IV collagen are accurate markers of histologically severe alcoholic hepatitis in patients with cirrhosis. *J. Hepatol.*; 32:412.
- **Castera L, Denis J, Babany G et al., (2007):** "Evolving practices of non-invasive markers of liver fibrosis in patients with chronic hepatitis C in France: Time for new gurdelines?". *J. Hepatol.* 46(3): 528-29.
- **Catarino RM, Lopez JD, Forones NM andet al., (2005):** Laminin concentration in ascites of patients with hepatic cirrhosis and peritoneal concinomatosis. *Braz. J Med Biol Res.*; 38(2): 271-6.

- **Chakrapani A and Green A. (2004):** Metabolic liver disease in the infant and older child. In: Kelly D, ed. Diseases of the liver and Biliary System in Children. Volum 1. 2nd ed. Malden, MA: Blackwell Publishing; Ltd.: 211-242.
- **Cho JJ, et al., (2000):** An oral endothelin-A receptor antagonist blocks collagen synthesis and deposition in advanced rat liver fibrosis. Gastroenterology. 2000.118:1169-1178. View this article via: PubMed CrossRef
- **Chou JY, Matern D, Mansfield BC, et al.,(2002):** Type I glycogen storage diseases: disorders of the glucose-6-phosphatase complex. Curr Mol Med:2:121-143.
- **Chung YH, Kim JA, Song BC and et al., (2000):** Expression of transforming growth factor-Alpha-mRNA in livers of patients with chronic viral hepatitis and hepato-cellular carcinoma. Cancer; 89: 977.
- **Clark DA and Coker R .(1998):** Transforming growth factor beta (TGF- β). Int. J. Biochem Cell Biol; 30(3): 293-298.
- **Colakoglu , taskiran B,Colkoglu G et al. (2007):** serum IGF1 and IGFBP3 levels in liver cirrhosis., Turk J gastroentrol 18 (4): 245-249.
- **Comanor L, Minor J, Conjeevaram HS,et al., (2001):** Impact of chronic hepatitis B and interferon-alpha therapy on growth of children. J Viral Hepatitis 8:139-1

- **Conichillo M, Prieto J and Quiroga J. (2007):** Insulin- like growth factor -I and liver cirrhosis S., *Rev Esp Enferm Dig*: 99 n(3): 156-64.
- **Cordoba J, Cabrera J, Lataif L, et al., (1998):** High prevalence of sleep disturbance in cirrhosis. *Hepatology*;27:339-45.
- **Corpechot C, et al. (2001):** Apolipoprotein E polymorphism, a marker of disease severity in primary biliary cirrhosis? *J. Hepatol.* 35:324-328. View this article via: PubMed CrossRef
- **Cortez A.P, Batista M and Matter R. (2009):** Food intake, Growth and body composition of children and adolescents with autoimmune hepatitis. *J clin Gastroenterol* . 22:26.
- **Crain M, Jaswon MS and Chew E. (1994):** Management of chronic disease. *Eur. J. Pediatr.*, 155: 326- 329.
- **Croquet V, Vuillemin E, Ternisien C and et al., (2002):** Prothrombin index is an indirect marker of severe liver fibrosis. *Eur J Gastroenterol Hepatol* ;14:1133-1141.
- **Cui W. and Jin HB. (2010):** Mechanism of TGF beta induction fibronectin expression in hepatic stem like cell. *Braz J Med Biol Res*, Vol 43 (1) 36-42.
- **Cutler N, (2009):** Why depression is likely with hepatitis C. *Hepatitis central. Com.*

- **Daniel MF, Peter K, Nadiya M, (2004):** Thomas Journal of Virology, May 2004, p. 5183, Vol. 78, No. 10
- **Dataller R, Paik YH, Lindquist, JN, et al., (2004):** Hepatitis C virus core and nonstructural proteins induce fibrogenic effects in hepatic stellate cells. Gastroenterology. 126:529-540. View this article via: PubMed CrossRef
- **Dataller R, et al.,(2003):** NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis. J. Clin. Invest. 112:1383-1394. doi:10.1172/JCI200318212. View this article via: JCI.org PubMed .Oben, JA, et al.
- **Davenport M (2005):** Biliary atresia. Seminars in pediatric surgery; 14(1): 42-48.
- **Davidson's (2002):** Liver and biliary tract diseases, Churchill Livingstone; 18: p848.
- **Davis GL, Albright JE, Cook SF,et al., (2003):** Projecting future complications of chronic hepatitis C in the United States. Liver Transpl. 2003.9:331-338. View this article via: PubMed CrossRef
- **McDiarmid SV, Gornbein JA, DeSilva PJ, et al.(1999):** Factors affecting growth after pediatric liver transplantation. Transplantation. 1999;67:404-411.
- **De Cock L, Hutse y, Verhaegen E,et al., (2004):** Detection of HCV antibodies in oral fluid. J Virol Methods; 122(2): 179-183.

- **De Crescenzo G, Hinck S, Shu Z, et al., (2006):** Three key residues underlie the differential affinity of the TGF-beta type II receptor. *J. Mol. Biol.*, 355(1): 47-62.
- **De Gouville AC, Boullay V, Krysa G, et al., (2005):** Inhibition of TGF-beta signaling by an ALK5 inhibitor protects rats from dimethylnitrosamine-induced liver fibrosis. *British Journal of Pharmacology*;145:166-177
- **Desmet VJ, Gerber M, Hoofnagle JH and et al, (1994):** Classification of chronic hepatitis: diagnosis, grading and staging. *Hepatology*; 19:1513-1520.
- **Dhawan A (2005):** Wilson's disease in children: 37-year experience and revised King's score for liver transplantation. *Liver Transpl*; 11(4): 441-448.
- **Dienstag JL (2002):** The role of liver biopsy chronic hepatitis C. *Hepatology*; 36(1):S152-S160.
- **Dixon JB, Bhathal PS, Hughes NR, et al., (2004):** Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss. *Hepatology*. 39:1647-1654. View this article via: PubMed CrossRef
- **Donaghy AJ, Delhanty PJ, Ho KK, et al.(2002):** Regulation of the growth hormone receptor/binding protein, insulin-like growth factor ternary complex system in human cirrhosis. *J Hepatol* 36(6): 751-8.

- **Donaldson P, et al., (2001):** HLA and interleukin 1 gene polymorphisms in primary biliary cirrhosis: associations with disease progression and disease susceptibility. *Gut.* 48:397-402. View this article via: PubMed CrossRef
- **Dooley S, et al., (2003):** Smad 7 prevents activation of hepatic stellate cells and liver fibrosis in rats. *Gastroenterology.* 125:178-191. View this article via: PubMed CrossRef.
- **Dotter CT (2004):** Catheter biopsy. Experimental technique for transvenous liver biopsy. *Radiology;* 82: 312-314.
- **Durum SK and Oppenheim JJ. (1993):** Pro-inflammatory cytokines and immunity. In: Paul WE (Ed.). *Fundamental Immunology.* Third edition, New York, Raven Press, PP.820-821.
- **Dwight MM, Kowdley KV, Russo JE, et al .,(2000):** Depression, fatigue, and functional disability in patients with chronic hepatitis C. *J Psychosom Res ;* 49:311+7.
- **Ekong U.(2007):** The treatment conundrum of neonatal hemochromatosis. *Pediatr Transplant ,* 11:347-348.
- **Elliott RL and Blobe GC. (2005):** Role of TGF beta in human cancer. *J.Clin.Oncol;* 23 : 2078-2093.
- **Ellis G, Goldberg DM, Spooner RJ and et al., (1987):** Serum enzyme tests in diseases of the liver and biliary tree. *Am. J. Clin. Pathol.;*70: 248-258.

- **El-Serag HB, Kunik M, Richardson P, et al., (2002):** Psychiatric disorders among veterans with hepatitisGastroenterology; 123: 476-482 PubMed
- **Elstein D, Abrahamov A and Hadas-HalpernI(2001):**Gaucher's disease. Lancet; 358: 324-327.
- **El-Tayeb M. (2001):** Beck depression inventory scale.Tanta university , faculty of arts.
- **El-Youssef M, Mu Y and Huang L. (1999):** Increased expression of transforming growth factor-beta 1 and thrombospondin-1 in congenital hepatic fibrosis: possible role of the hepatic stellate cell. J Pediatr Gastroenterol Nutr; 28(4):386-92.
- **Emerick KM and Whittington PF (2006):** Neonatal liver disease. Pediatric Annals; 35(4): 280-286.
- **Endo F and Sun MS. (2002):** Tyrosinaemia type I and apoptosis of hepatocytes and renal tubular cells. J Inher Metab Dis;25:227-234 .
- **Esmat G, Metwally M, Zalata KR and et al., (2007):** Evaluation of serum biomarkers of fibrosis and in Egyptian patients with chronic hepatitis C. J. Hepatol; 46(4): 620-7.
- **Feld JJ and Heathcote EJ . (2003):** Epidemiology of autoimmune liver disease. J Gastroenterol Hepatol18:1118-1128.
- **Fernandez-Rodriguez CM, Prada I, Andrade A, et al.,(2001):** Disturbed synthesis of insulin like growth factor I and its bin

- ding proteins may influence renal function changes in liver cirrhosis. *Dig Dis Sci* ; 46(6): 1313-20.
- **Ferreira AR, Roquete MLV, Penna FJ, et al., (2002):** Hepatite auto-imune em crianças e adolescentes: estudo clinico, diagnostico e resposta terapeutica (Autoimmune hepatitis in children and adolescents: clinical study, diagnosis and therapeutic response). *J Pediatr (Rio J)*.;78:309-3 14.
 - **Firth SM, Ganeshprasad U, Baxter RC (1998):** "Structural determinants of ligand and cell surface binding of insulin-like growth factor-binding protein-3". *J. Biol. Chem.* 273 (5): 2631–8.
 - **Fischer HP, Ortiz-Pallardo ME, Ko Y, et al., (2000):** Chronic liver disease in heterozygous alpha 1-antitrypsin deficiency PiZ. *Hepatol* ;33:883-892.
 - **Flisiak R, Pytelkrolczuk B and Prokopowicz D(2000):** Circulating transforming growth factor beta(1) as an indicator of hepatic function impairment in liver cirrhosis. *Cytokine.* ; 12: 677-81.
 - **Flisiak R and Prokopowicz D.(2000):** Transforming growth factor-beta 1 as a surrogate marker of hepatic dysfunction in chronic liver diseases. *Clin Chem Lab Med*;38:1129-31.
 - **Flisiak R, Maxwell P, Prokopowicz D, et al.,(2002):** Plasma tissue inhibitor of metallopro-teinasas-1 and transforming growth factor beta 1 as Possible non-invasive biomarkers of hepatic fibrosis in patients with chronic B and C hepatitis. *Hepato-Gastroenterol.* 49:1369-72.

- **Floreani A, Rizzotto ER, Ferrara F, et al.,(2005):** Clinical course and outcome of autoimmune hepatitis/primary sclerosing cholangitis /overlap syndrome. *Am J Gastroenterol* 100:1516-7X 1522.
- **Fontana RJ and Lok ASF. (2002):** Noninvasive monitoring of patients with chronic hepatitis C. *Hepatology*; 36:S57-S64
- **Forns X, Ampurdanes S, Liovet JM and et al., (2002):** Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. *Hepatology*. 36(4pt 1): 986-92.
- **Foster JH, Peters TJ and Marshall E.I . (2000):** Quality of life measures and outcome in alcohol-dependent men and women. *Alcohol*:22:45-52.
- **Foynard T, Ratziu V and Bedossa P. (2000):** Appropriateness of liver biopsy C. *J. Gastroenterol.*; 14: 543-548.
- **Franco LM, Krishnamurthy V, Bali D, et al.,(2005):** Hepatocellular carcinoma in glycogen storage disease type Ia: a case series. *J Inherit Metab Dis*:28:153-162.
- **Friedman LS. (2004):** Controversies in liver biopsy: who, where, when, - how, why?. *Curr Gastroenterol Rep*; 6(1): 30-36.
- **Friedman S and Keefe B (2004):** Cirrhosis and portal hypertension. In *Hand Book of Liver disease* Friedman S. Keefe B: P 125-132.
- **Friedman SL, et al. (1992):** Isolated hepatic lipocytes and Kupffer cells from normal human liver: morphological and functional

- characteristics in primary culture. *Hepatology*. 15:234-243. View this article via: PubMed CrossRef
- **Friedman, SL.(2003):** Liver fibrosis - from bench to bedside. *J. Hepatol.* . 38(Suppl. 1):S38-S53.View this article via: PubMed .
 - **Gabele E, Brenner DA and Rippe RA.(2003):** Liver fibrosis: signals leading to the amplification of the fibrogenic hepatic stellate cell. *Front. Biosci.* 8:D69-D77. View this article via: PubMed CrossRef
 - **Galli, A, et al., (2002):** Anti-diabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. *Gastroenterology*. 122:1924-1940. View this article via: PubMed CrossRef
 - **Garcia-Fernandez M, Castilla-Cortazar I, Diaz-Sanchez M, et al., (2003):** Effect of IGF-1 on total serum antioxidant status in cirrhotic rats. *J Physiol Biochem* 59: 145-6.
 - **Gerlach JT, Diepolder HM, Zachoval R and et al, (2003):** Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. *Gastroenterology*; 125: 80-88.
 - **Ghaly Isis, et al., (2002):** National Growth Charts for Egypt.
 - **Giannini E, Risso D, Botta F and et al., (2003):** Validity and clinical utility of the aspartate aminotransferase- alanine aminotransferase ratio in assessing disease severity and prognosis in patients with

- hepatitis C virus- related chronic liver disease. Arch Intern Med; 163:218-224.
- **Gines P, Cardenas A, Arroyo V, et al. (2004):**Management of cirrhosis and ascites. N. Engl. J. Med. 350:1646-1654.View this article via: PubMed CrossRef
 - **Glacken M, Coates V, Kcrnohan G, et al.,(2003):**The experience fatigue for people living with hepatitis C. J Clin Nurs; 12:244-252.
 - **Gonzalez Calvin JL, Gallego-Rojo F, Fernandez-Perez R, et al.,(2004):** Osteoporosis, mineral metabolism, and serum soluble tumor necrosis factor receptor p55 in viral cirrhosis. J Clin Endocrinol Metab ; 89(9): 4325-30.
 - **Gonzalez-Peralta RP, Kelly DA, Haber B, et al.(2005):** Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharmacokinetics. Hepatology 2005; 42:1010-8.
 - **Gordon SC, Fang J W, Silverman AL and et al.,(2000):** The significance of baseline serum alanine aminotransferase on pretreatment disease characteristics and response to therapy in chronic hepatitis C. Hepatology; 32: 400-404.
 - **Gottlieb SS.,Khatta M, Friedman E, et al ., (2004):** The influence of age, gender, and race on the prevalence of depression in heart failure patients. J Am Coll Cardiol:43:1542-9.

- **Gottschall CBA, Alvarez-da-Silva MR, Camargo ACR, et al., (2004):** Avalia9ao nutritional de pacientes com cirrose pelo virus da hepate C: a aplicacao da calorimetria indireta (Nutritional evolution of patients with cirrhosis by hepatitis C virus: the application of indirect calorimetry). *Arq Gastroenterol.*;41:20-224.
- **Gow PJ and Mutimer D. (2001):** Treatment of chronic autoimmune hepatitis . *Hepatology*, 323:1164-3166.
- **Grabhom E, Richter A, Burdelski M, et al., (2006):** Neonatal hemochromatosis ; long-term experience with favorable outcome. *Pediatrics*; 118:2060- 2065.
- **Greerts A. (2001):** History, heterogeneity, developmental biology, and functions of quiescent hepatic stellate cells. *Semin Liver Dis*; 21: 311-
- **Gregorio GV, Portmann B, Karani J, et al., (2001):** Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a i6-year prospective study. *Hepatology* 533:544-553.
- **Gressner AM, Weiskirchen R, Breitkopf K,et al., (2002):** Roles of TGF-beta in hepatic fibrosis. *Front. Biosci.* 2002. 7:d793-d807. View this article via: PubMed CrossRef
- **Gressner AM. (1998):** The cell biology of liver fibrogenesis-an imbalance of proliferation, growth arrest and apoptosis of myofibroblast. *Cell Tissue Res*; 292: 447-452.
- **Gressner G.A, Weiskirchen, R and Gressner A.M (2007):** Biomarkers of hepatic fibrosis, fibrogenesis and genetic predisposition

- pending between fiction and reality. J.Cell . Med. Vol 11, No 5, 1031-1054.
- **Grigorescu M (2006):** Non-invasive biochemical markers of liver fibrosis. J Gastrointest. Liver Dis.; 15(2): 149-59.
 - **Gross CR, Malinchoc M. Kim WR, et al., (1999):** Quality of life after liver transplantation for cholestatic liver disease. Hepatology 1999;29:356-64.
 - **Grossi E, Mosconi P, Groth N,et al.,(2002):** PGWBI: Questionario Psychological General Well-Being Index, version italiana. Milano: Istituto di Ricerche farmacologiche "Mario Negri".
 - **Groth CG, Ringden O(1984):** Transplantation in relation to the treatment of inherited disease. Transplantation 38
 - **Guechot J, Poupon RE and Poupon R (1995):** Serum hyaluronan as a marker of liver fibrosis. J Hepatol; 22 (suppl 2): 103-106.
 - **Guectybt J, Serfaty L, Bonnand A and et al., (2000):** Prognostic value of serum hyaluronan in patients with compensated HCV cirrhosis. J. Hepatol.; 32: 447.
 - **Hanif M, Raza J, Qureshi H et al. (2004):** Etiology of liver disease in children. J Pak Med Assoc;54(3): :119-122.
 - **Hasen K and Horselen S, (2008):** Metabolic liver disease in children liver Transplant 14:391-411.

- **Herman-Giddens, M.E, Slora, E.J. and Wasserman, R.C. *et al.*, (1997):** Secondary sexual characteristics and menses in young girls seen in office practice: a study from the pediatric research in office settings network. *Pediatrics*, 99: 501-12.
- **Heubi JE, Heyman MB. and shalman RJ (2002):** the impact of liver disease on growth and nutrition, *pediatric Gastenoentrology and Nutrition* 35:S55-S59.
- **Higuchi H. and Gores GJ. (2003):** Mechanisms of liver injury: an overview. *Curr. Mol. Med.* 3:483-490. View this article via: PubMed CrossRef 51.
- **Hinoshita E, Taguchi K, Inokuchi A and et al., (2001):** Decreased expression of an ATP- binding cassette transporter, MRP2, in human "livers with hepatitis C virus infection. *J. Hepatol.*; 35: 765-773.
- **Hirata M, Akbar SM, Horiike N and et al.,(2001):** Noninvasive diagnosis of the degree of hepatic fibrosis using ultrasonography in patients with chronic liver disease due to hepatitis C virus. *Eur. J. Clin. Invest.* 31:528-535. View this article via: PubMed CrossRef
- **Hjortswang H, Jarnerot G, Curman B, et al (2003):** The influence of demographic and disease-related factors on health-related quality of life in patients with ulcerative colitis. *Eur J Gastroenterol Hepatol*:15:1011-20.
- **Hoppener J W, de Pagter-Holthuizen P, Geurts van Kessel AH, et al., (1985).** "The human gene encoding insulin-like growth factor 1 is

- located on chromosome 12". Hum. Genet. 69(2):
(<http://dx.doi.org/10.1007%2F00293288>)PM1D.
- **Horslen S.(2004):** Carbohydrate metabolism. In: Walker WA, Goulet O, Kleinman RE, Sherman PM, Shneider BL, Sanderson IR, eds.:Pediatric Gastrointestinal Disease: Pathophysiology, Diagnosis, Management. Volume 2. 4th ed. Ontario, Canada: BC Decker, Inc. 1257-1274.
 - **Huang J and Rosenthal P. (2000):** Interferon therapy in pediatric chronic hepatitis B infection warranted J. (Pediatr. Gastroenterol. INutr.31:217.
 - **Huet PM, Deslauners J. Trail A et al.,(2000):**Impact of fatigue on the quality of life of patients with primary biliary cirrhosis. Am J Gastroenterol:5:760-7.
 - **Imbert-Bismuth F, Ratziu V, Pieroni L and et al., (2001):** Biochemical markers of liver fibrosis in patients with hepatitis C infection: a prospective study. Lancet; 357(7): 1069-1075.
 - **Infante Rivard C, Esnaola S, Villeneuve J- P (1987):** Clinical and statistical validity of conventional prognostic factors in predicting short term survival among cirrhotics: 7: 660.
 - **Ishak K, Baptisa A, Bianchi L and et al., (1995):** Histological grading and staging of chronic hepatitis. J. Hepatol.; 22:696-699.
 - **Issa R, et al.,(2004):** Spontaneous recovery from micronodular cirrhosis: evidence for incomplete resolution associated with matrix

- cross-linking. *Gastroenterology*. 126:1795-1808. View this article via: PubMed CrossRef 124.
- **Jacobson KR, Murray K, Zellos A, et al.,(2002):** An analysis of published trials of interferon monotherapy in children with chronic hepatitis C. *J. Pediatr. Gastroenterol. Nutr.* 2002; 34:52-8.
 - **James M. and Perrin, P. (2004):** Impact of chronic illness. In: Nelson textbook of pediatrics. 17th edition. Behrman, RE, Gligman RM RE, Gligman RM, Nelson VC (eds) Saunders Co Philadelphia, London, Toronto chapter 17: 121-124.
 - **Johansen J, Christoffers P, Matter S and et al., (2000):** Serum (YKL-7 40) a potential new serum fibrosis marker in patients with alcoholic liver disease. *Eur. J. Gastroenterol. Hepatol.*; 12: 989.
 - **Jonas MM, Kelly DA, Mizerski J,et al., (2002):** The international Pediatric Lamivudine investigator Group. Clinical trial of lamivudine in children with chronic hepatitis B.*N Engl J Med* 346:1706-1713.
 - **Jonas MM. (2000):** Hepatitis C in children. In *Hepatitis C*, Liang TJ and Hoofnagle JH, eds. Biomed Res Rep; San Diego, CA, Academic Press, p. 389-404.
 - **Kamal SM. (2008):** "Acute hepatitis C: a systematic review". *The American Journal of Gastroenterology* 103 (5): 1283-97; quiz 1298. doi:10.1055/j.1572-0241.2008.01825.x.PMID18477352.
 - **Kamel MH.(2010):** prevalence of depression and cognitive impairment in hepatitis C infected patients. Thesis. Ain shams university 84-94

- **Kanno K, Tazuma, S and Chayama, K.(2003):** Alpha 1 antitripsin-deficient mice show less severe progression of liver fibrosis induced by CC1(4). *Biochem. Biophys. Res. Commun.* 308:177-183.
- **Karagiannis A and Harsoulis F. (2005):** Gonadal dysfunction in systemic disease. *Eu Journal of endocrinology* vol 152 Issu 4, 501-513.
- **Karim A, Ahmed S, Khan A, Steinberg H, Mattana J. (2004):**The epidemiology of hepatitis C in Egypt in the *Afro-Arab Liver Journal*, (July), vol 3, No2,), pp 41-52.
- **Keating GM. (2008).** "Mecasermin". *BioDrugs* 22 (3): 177-88. doi: 10.2165/00063030-200822030-QQ004
- **Kelley DA, Bunn SK, Apelian D, et al.,(2001):** Safety, efficacy and pharmacokinetics of interferon alfa-2b plus ribavirin in children with chronic hepatitis C (abstract). *Hepatology*; 34:342A.
- **Kelly DA, Portmann B, Mowat AP,et al.,(2003):** Metastatic hepatocellular carcinoma in a patient with Niemann-Pick disease, type C. *J Pediatr Gastroenterol Nutr*:37:624-626.
- **Khan JA, Khan FA, Dilawar M and et al., (2007):** Serum hyalmonic acid as a marker of hepatic fibrosis. *J Coll Physcians Smgpak*; 17(6):323-6.
- **Khattab DM. (2004):** Plasma carnitine status of children with chronic liver disease and cirrhosis. Thesis, Ain Shams University. .

- **Kimberly LB . (2005):** Percutaneous liver biopsy coated from Handbook of Gastroenterologic procedure fifth Edition (11)P. 78-83, published by LIPPINCOTT WILLIAMS & WILKINS.
- **Kinnman, N, Housset, C. (2002):** Peribiliary myofibroblasts in biliary type liver fibrosis. Front. Biosci. 7:d496-d503. View this article via: PubMed CrossRef
- **Kirmaz C, Terzioğlu E, Topalak O, et al., (2004):** Serum transforming growth factor-beta 1 (TGF- beta1) in patients with cirrhosis, chronic hepatitis B and chronic hepatitis C. Eur Cytokine Netw; 15(3):272.
- **Klein AS and Molmenti EP (2003):** Surgical treatment of Budd-Chiari syndrome. Liver Transpl; 9: 891-896.
- **Kmiec Z. (2001):** Cooperation of liver cells in health and disease. Adv. Anat. Embryol. Cell Biol. 2001. 161:III-XIII, 1-151. View this article via: PubMed
- **Knauer MC (1978):** Percutaneous biopsy of the liver as a procedure for outpatients. Gastroenterology; 74: 101-102.
- **Knodell RG, Ishak KG, Black WC and et al., (1981):** Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. J. Hepatology; 1:431-435.
- **Lawrence DA (2001):** Latent TGF-beta: an overview. Mol. Cell. Biochem., 219: 163-170.

- **Leask A and Abraham DJ (2004):** TGF-beta signaling and fibrotic response. *FASEB J*; 18: 816-817.
- **Leask A and Abraham DJ (2006):** All in the CCN family: essential multicellular signaling modulators emerge from the bunker. *J Cell Sci*; 119.
- **Lebenztein DM, Lotwys M, Kaczmarz M, et al.,(2004):** Serum concentration of TGF β does not predict advanced liver fibrosis in children with chronic hepatitis B, *Hepato-gastroenterology* Jan-Feb 51(55):299-33.
- **Lee B and Goss J.(2001):** Long-term correction of urea cycle disorders. *J Pediatr*:138:S62-S71.
- **Leonard JV and Morris AA.(2002):** Urea cycle disorders. *Semin Neonatol* 2002;7:27-35.
- **Leonard JV. And McKiernan PJ.(2004):** The role of liver transplantation in urea cycle disorders. *Mol Genet Metab*; 81(suppl 1):S74-S78.
- **Li CP, Lee FY and Hwang SJ. (1999):** Spider angiomas in patients with liver cirrhosis: Role of alcoholism and impaired liver function. *Scand. J. Gastroenterol*; 34 (5): 520-523.
- **Liberek A, Marek A, Kimecz et al., (2009):** Role of TGF β 1 in the pathogenesis. And clinical course of chronic hepatitis in children, *Med weku Ro zowj* Jul-Sept 13(3)-162-70.

- **Lindquist JN, Parsons CJ, Stefanovic B, et al.,(2004):** Regulation of alpha 1 collagen messenger RNA decay by interactions with alpha CP at the 3- untranslated region. *J. Biol. Chem.* 279:23822-23829. View this article via: PubMed CrossRef
- **Lindquist JN, Marzluff, WF and Stefanovic, B. (2000):** Fibrogenesis. III. Posttranscriptional regulation of type I collagen. *Am. J. Physiol. Gastrointest. Liver Physiol.* 2000. 279:G471-G476. View this article via: PubMed
- **Magness ST, Bataller R, Yang, L, et al., (2004):** A dual reporter gene transgenic mouse demonstrates heterogeneity in hepatic fibrogenic cell populations. *Hepatology.* 40:1151 -1159. View this article via: PubMed CrossRef
- **Maher JJ, Zia S and Tzagarakis C. (1994):** Acetaldehyde- induced stimulation of collagen synthesis and gene expression is dependent on conditions of cell culture: studies with rat lipocytes and fibroblasts. *Alcohol Clin. Exp. Res.* 18:403-409. View this article via: PubMed CrossRef
- **Maher JJ. (2001):** Interactions between hepatic stellate cells and the immune system. *Semin. Liver Dis.*21:417-426. View this article via: PubMed CrossRef 55.
- **Mann DA and Smart DE.(2002):** Transcriptional regulation of hepatic stellate cell activation. *Gut.* 50:891-896. View this article via: PubMed CrossRef

- **Marceau G, Lapierre P, Beland K, et al.,(2005):** LKMi autoantibodies in chronic hepatitis C infection: a case of molecular mimicry? *Hepatology* 42:675-682.
- **Marcellin P, Asselah T and Boyer N (2005):** Chronic Hepatitis B. In *Clinical Gastroenterology and Hepatology* 1st edition. Weinstein MW, Howkey CJ and Bosch J; Ch 82A: 595:600.
- **Marchesini G. et al.,(2001):** Italian Study Group for Quality of Life in sis. Factors associated with poor health-related quality of life of patients with cirrhosis. *Gastroenterology*:120:170-8.
- **Marra F.(1999)** Hepatic stellate cells and the regulation of liver inflammation. *J. Hepatol.* 31:1120- 1130. View this article via: PubMed CrossRef .
- **Marshall WA, Tanner JM. (1970):** Variations in the pattern of pubertal changes in boys. *Arch Dis Child.*;45:13-23.
- **Marshall WA, Tanner JM.(1969):** Variations in pattern of pubertal changes in girls. *Arch Dis Child.*;44:291-303.
- **Massague J, Seoane J and Wotton D (2005):** Smad transcription factors. *Genes Dev.*; 19: 2783-281U.
- **Massague J , Blain SW and Lo RS (2000) :**TGF-beta signaling in growth control, cancer, and heritable disorders. *Cell* ; 103: 295-309.
- **Massague J and Wotton D (2000):** Transcriptional control by TGF-beta Smad signaling system. *EMBO J*; 19: 1745-1754.

- **Matos C, Porayko MK, Francisco-Ziller N, et al.(2002):** Nutritional and chronic liver disease. *J Clin Gastroenterol*. 2002;35: 391-397.
- **Mattar RHGM, Azevedo RA, Speridiao PGL, et al.,(2005):** Estado nutricional e absorcao intestinal de ferro em crian?as F portadoras de doenja hepatica cronica com e sem colestase (Nutritional status and intestinal iron absorption in children with chronic hepatic disease with or without cholestasis). *J Pediatr (Rio J)*.;8 1:31 7-324.
- **Mattera D, Capuano G, Colao A, et al .,(2003):** Increased IGF1 : IGFBP-3 ratio in patients with hepatocelular carcinoma. *Clin Endocrinal (OXF)* Dec; 59 (6). 699-706.
- **McAndrews MP, Farcnik K, Carlen P,et al., (2005):** Prevalence and significance of neurocognitive dysfunction in hepatitis C in the absence of correlated risk factors. *Hepatology*; 41:801-808.
- **McDiarmid SV, Gornbein JA, DeSilva PJ, et al. (1999):** Factors affecting growth after pediatric liver transplantation. *Transplantation*, 67:404-411.
- **McFarlane IG. (2002):** Autoimmune hepatitis: diagnostic criteria, subclassifications, and clinical features. *Clin Liver Dis*16:317-333.
- **McInyre N. (1996):** The Child- Turcotte and Child- Pugh classification. In Rcichen J. Poupon RE. *Surrogate markers to asses efficacy of treatment in chronic liver disease*. London: Kluwer Academic Publishers; P.69.

- **McKusick MA. (2001):** Imaging finding in Budd-Chiari syndrome. Liver Transpl; 7(8): 743-744.
- **Melis D,Pivonella R,Parenti G, et al.,(2010):**The growth hormone-insulin like growth factor axis in glycogen storage disease type 1 in. the Journal of Pediatric :669-678
- **Mendenhall CL, Roselle GA, Gartside F,et al.,(1997):** Effects of recombinant human insulin-like growth factor-1 and recombinant human growth hormone on anabolism and immunity in calorie restricted alcoholic rats. Alcohol Clin Exp Res 21: 1-10.
- **Menon KV, Shah V and Kamath PS. (2004):** The Budd-Chiari syndrome. N Engl J Med; 350(6): 578-585.
- **METAVIR: The French METAVIR Cooperative Study Group (1994):** Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology, 20: 15-20.
- **Mezeban Z and Wakil A.(2006):**Hepatitis C in Egypt (the medicalwriter'scircle).<http://www.SSilink.org>
- **Michael LB, Edward PF and Larry S. (2005):** Amino acids and proteins; 8: 196-197. In: Clinical Chemistry; principles, procedures and correlations. 5th ed. Lippincott Williams & Wilkins, Philadelphia USA.
- **Michael P and Nezam H. (2003):** Serum markers of hepatic fibrosis. [www. Uptodate.com](http://www.Uptodate.com).

- **Mills CT, Lee E and Perrillo R. (1990):** Relationship between histology, aminotransferase levels and viral replication r chronic hepatitis B. *Gastroenterology*; 99: 519.
- **Murawaki F, Koda M, Okamoto K and et al., (2001):** Diagnostic value of serum type IV collagen test in comparison with platelet count for predicting the fibrotic stage in patients with chronic hepatitis C. *J. Gastroenterol. Hepatol.*; 16: 777.
- **Murawaki Y, Ikuta Y, Idobe Y et al., (1999):** Serum matrix metalloproteinase-1 in patients with chronic viral hepatitis. *J. Gastroenterol Hepatol*, 14: 138-45.
- **Myers RP, Messous D, Thabut D and et al., (2002):** The prediction of fibrosis with serum biochemical markers in patients with chronic hepatitis C. Prospective validation in 534 patients. *Hepatology*; 36: 351A (Abstract).
- **Naito M, Hasegawa G, Ebe Y, et al., (2004):** Differentiation and function of Kupffer cells. *Med. Electron Microsc.* 2004. 37:16-28.
View this article via: PubMed CrossRef
- **Naveau S, Poynard T, Benattar C and et al, (1994):** Alpha-2-macroglobulin and hepatic fibrosis. *Diagnostic Interest. Dig. Dis. Sci.*; 39: 2426-2432.
- **Nazer H. (2008):** Congenital hepatic fibrosis.
<http://www.emedicine.com/ped/TOPI459.HTM>

- **Needlman, R.D. (2008):** Growth and development. In: Nelson textbook of Pediatric, Chapter 14, 53:57.
- **Neuman MG (2001):** Apoptosis in diseases of the liver. Crit. Rev. Clin. Lab. Sci., 38:109-166.
- **Ngo Y, Munteanu M, Messous D and et al., (2006):** A prospective analysis of the prognostic value of biomarkers (fibrotest) in patients with chronic hepatitis C. Clin Chem; 52(10): 1887-96.
- **Nicolau C, Bianchi L and Vilana R. (2002):** Gray-scale ultrasound in hepatic cirrhosis and chronic hepatitis: diagnosis, screening and intervention. Seminars in US, CT and MRI;23:3-18.
- **Nishiura T, Watanable H, Matsuoka Y and et al., (2005)** "Ultrasound evaluation of the fibrosis stage in chronic liver disease by simultaneous use of low and high frequency probes" British Journal of radiology 78, 189-197
- **. Novy MA, Shwarz KB (1997):** Nutritional considerations and management of the child with liver disease. Nutrition; 13:177-84
- **Oben JA, Yang S, Lin H, et al., (2003):** Norepinephrine and neuropeptide Y promote proliferation and collagen gene expression of hepatic myofibroblastic stellate cells. Biochem. Biophys. Res. Commun. 302:685-690. View this article via: PubMed CrossRef
- **Olaso E, et al., (2001):** DDR2 receptor promotes MMP-2-mediated proliferation and invasion by hepatic stellate cells. J. Clin. Invest, 108:1369-1378. View this article via: JCI.org PubMed.

- **Onsy A. (2008):** Study of serum transforming growth factor- beta 1 level in children with chronic liver disease. . Thesis. Ain shams university 78-79
- **Ottesen LH, Bendtsen F, and Flyvbjerg A.(2001):** The insulin-like growth factor binding protein 3 ternary complex is reduced in cirrhosis. *Liver* 21(5): 350-6.
- **Paik YH, et al., (2003):** Toll-like receptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells. *Hepatology*. 37:1043-1055. View this article via: PubMed CrossRef 118.
- **Palmer M. (2004):** Fatigue and liver disease in Palmer's guide of Hepatitis and Liver Disease.www.Liverdisease.com
- **Paradis V, Mathurin P, Ratziau V and et al., (1996).** Binding of apolipoprotein AI and acetaldehyde-modified apolipoprotein AI to liver extracellular matrix. *Hepatology*; 23: 1232-1238.
- **Patch D. (2005):** Liver biopsy chapter 134 coated from clinical gastroenterology and hepatology 1st Edition. Page 987 to 991 chapter 134.
- **Peck-Radoslavljevic M. (2001)** Hypersplenism. *Eur J Gastroenterol Hepatol*; 13:317-323.
- **Petruff A and Chopra S. (1998):** Cirrhosis and portal hypertension. *Liver disease* 1st edition 9:125-138. Churchill Livingstone.

- **Phillips, RJ, et al. (2004):** Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. *J.Clin.Invest.* 114:438-446. doi:10.1172/JCI200420997. View this article via: JCI.org PubMed
- **Piccinino F, Sagnelli E, Easquale G and et al., (1986):** Complications following percutaneous liver biopsy: a multicentre retrospective study on 68, 276 biopsies. *J. Hepatology*; 2:165.
- **Pinzani M. (2002):** PDGF and signal transduction in hepatic stellate cells. *Front. Biosci.* 7:dl720-d!726. View this article via: PubMed
- **Pinzani M. (2006):** Non- invasive evaluation of hepatic fibrosis: don't count your chicken before they're hatched *Gut*, 55:310-312.
- **Pinzani M, Rombouts K and Colagrande S. (2005):** Fibrosis in chronic liver diseases: diagnosis and management. *J Hepatol.* 42: S12-S36.
- **Pinzani M and Marra F. (2001):** Cytokine receptors and signaling in hepatic stellate cells. *Semin Liver Dis* , 21 : 397-416.
- **Pitette C, Oberti F, Aube C and et al., (1999):** Non invasive diagnosis of esophageal varices in chronic liver disease. *J Hepatol*; 31 : 867-873.
- **Poorten V, Kenny DT, Butler T et al., (2007):** Liver disease in adolescents. A cohort study of high-risk individuals, *Hepatology*. Dec;4216:1750-8.

- **Popper H and Uenfriend S.(1970):** Hepatic fibrosis. Correlation of biochemical and morphologic investigations. Am. J. Med. 49:707-721.View this article via: PubMed CrossRef J
- **Poynard T, Munteanu M, Imbert-Bismut F and et al., (2004):** Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C. Clin chem.50(8): 1344-55.
- **Poynard T, Bedossa P, Mathurin P and et al., (1995):** Apolipoprotein A1 and hepatic fibrosis. J. Hepatol.; 22: 107-110.
- **Poynard, T, et al., (2000):** Natural history of HCV infection. Baillieres Best Pract. Res. Clin. Gastroenterol..14:211-228. View this article via: PubMed CrossRef
- **Rake JP, van Spronsen FJ, Visser G, et al., (2000):** End-stage liver disease as the only consequence of a mitochondria! Respiratory chain deficiency: no contra-indication for liver transplantation. EurJ Pediatr; 159:523-526.
- **Ramaccioni, Valerig, Wllsam J. et al., (2000):** Nutritional aspects of chronic liver disease and liver Transplantation In children in Journal of pediatric Gastroenterology and Nutrition, vol 30:361-367.
- **Ramadori G and Saile, B. (2004):** Portal tract fibrogenesis in the liver. Lab. Invest. 84:153-159. View this article via: PubMed CrossRef

- **Rand E. Karpen S, Zwiener RJ, et al., (2006):** Treatment of neonatal hemochromatosis based on alloimmune causation. *Hepatology* 2006;44:435A.
- **Raslan H, Mohamed W. and Mahomouel M. (2007):** Insulin growth factor and insulin, growth factor binding protein3- in Egyptian patients with chronic hepatitis C *Arch Med Sci* 3, 1: 46-51.
- **Rocca P, Couzza E, Rasetti R, et al.,(2003):** Predictors of psychiatric disorders in liver transplantation candidates: logistic regression models. *Liver Transpl*; 9:721-6.
- **Rodger AJ, Jolley D. Thompson SC, et al.,(1999):** The impact of diagnosis of hepatitis C virus on quality of life. *Hepatology*;30:1299-301.
- **Rodrigues F, Kallas M, Nash R, et al.,(2005):** Neonatal hemochromatosis medical treatment vs. transplantation: the King's experience. *Liver Transpl*;11:1417-1424.
- **Rodriguez N, wayman K. and COX K (2001):** Growth and development in chronic liver disease. *NeoReview* vol2 no9.
- **Rodriguez-Roisin R, Krowka MJ, Herve P and Fallen MB (2004):** ERS Task Force Pulmonary-Hepatic Vascular Disorders (PHD) Scientific Committee. Pulmonary-Hepatic vascular Disorders (PHD). *Eur Respir J*; 24: 861-880.
- **Rosenthal P. (2000):** Is our approach to treating chronic hepatitis C all wrong? *J. Pediatr.Gastroenterol. Nutr*; 31:100.

- **Rothenthal P. (2006):** Hepatitis B and C in children indate; The Medical writer 's circle.www.Hcvadvocate.org
- **Roy PK and Barakat J. (2006):** Budd-Chiari syndrome. E Medicine accessedat: <http://www.emedicine.com/med/topic2694.htm>
- **Russo PA. Mitchell GA and Tanguay RM.(2001):**Tyrosinemia: a review. *Pediatr Dev Pathol*:4:212-221.
- **Ryckeman FC and Alonso MH. (2001):** Causes and management of portal hypertension in the pediatric population. *Clin Liver Dis*; 5: 789-818.
- **Safadi R, et al. (2004):** Immune stimulation of hepatic fibrogenesis by CDS cells and attenuation by transgenic interleukin-10 from hepatocytes. *Gastroenterology*. 127:870-882. View this article via: PubMed CrossRef
- **Sato M, Suzuki S and Senoo H. (2003):** Hepatic stellate cells: unique characteristics in cell biology and phenotype. *Cell Struct. Funct*. 28:105-112. View this article via: PubMed CrossRef
- **Schaffher F and Klion FM.(1968):** Chronic hepatitis. *Annu. Rev. Med.* . 19:25-38. View this article via: PubMed CrossRef
- **Schilsky ML and Tavill AS. (2007):** Wilson's disease. In Schiff ER, Sorrell M, Maddrey W (eds) *Schiffs Diseases of the Liver*, 10th ed. Philadelphia, Lippincott Williams & Wilkins, pp 1023-1040.

- **Schuppan, D, Krebs, A, Bauer, M,et al., (2003):** Hepatitis C and liver fibrosis. *Cell Death Differ.* 10(Suppl. 1):S59-S67. View this article via: PubMed CrossRef
- **Schuster N and Krieglstein K (2002):** Mechanism of TGF beta-mediated apoptosis. *Cell tissue Res*; 307: 1-14.
- **Schwabe RF, Schnabl B, Kweon,YO, et al., (2001):** CD40 activates NF-kappa B and c-Jun N-terminal kinase and enhances chemokine secretion on activated human hepatic stellate cells. *J. Immunol.* 2001. 166:6812-6819. View this article via: PubMedCrossRef
- **Schwabe RF, et al.,(2004):**Differential requirement for c-Jun NH2-terminal kinase in TNFalpha- and Fas-mediated apoptosis in hepatocytes. *FASEB J.* 18:720-722.View this article via: PubMed
- **Schwarz SM (2007):** .Biliary atresia. Accessed <http://www.emedicine.com/PED/topic237.htm>
- **Seth A and Aggarwal A.(2004):** Monitoring adverse reactions to steroid therapy in children. *Indian Pediatr.* 2004;4:349-357.
- **Shepherd J, Brodin H, Cave C,et al., (2004):** Pegylated interferon alpha.-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: A systematic review and economic evaluation. *Health Technol Assess*; 8(39): 1-125.
- **Sherlock S and Dooley J. (2002):** Anatomy and function; Biopsy of the liver and hepatic cirrhosis. In *Diseases of the liver and Biliary*

- system "11th Edition", Blackwell Sc. Publ., Oxford, London, Edinburgh, (1): 1-16; (3): 37-44 and (21): 365-377.
- **Sherlock S. and Dooley J. (2002b):** Hepatic cirrhosis, Disease of the liver and biliary system. "Eleventh edition" Blackwell Science Publ; 21:365-380.
 - **Shi Y and Massague J.(2003):** Mechanisms of TGF-beta signaling from cell membrane to the nucleus.; 113: 685- 700. Links
 - **Singh N, Gayowski T, Wagener MM, et al.,(1997):** Vulnerability to psychological distress and depression in patients with end-stage liver disease due to hepatitis C virus. Clin Transplant:11:406-11.
 - **Singh N, Gayowski T, Wagener MM,et al.,(1997):** Depression in patients with cirrhosis. Impact on outcome. Dig Dis Sci; 42:1421-7.
 - **Singh R, Nair S, Fair G, et al.,(2002):** Acute autoimmune hepatitis presenting with centrizonal liver disease: case report and review of the literature. Am J Gastroenterol 97:2670-2673.
 - **Snyder JD and Pickering LK. (2008):** Viral hepatitis. In: Behrman RE, Kliegman RM and Jenson HB (Eds): NELSON text book of pediatrics, 17th ed. SAUNDERS, chapter 339, pp 1324-1331.
 - **Sokol K and Stall M. (1995):** Anthropometric evaluation of children with chronic liver diseases. Am J clin nutr.,52:203-200.
 - **Soyer MT, Ceballos R and Aldrete, JS. (1976):** Reversibility of severe hepatic damage caused by jejunoileal bypass after re-

- establishment of normal intestinal continuity. *Surgery*; 79:601-604. View this article via: PubMed .
- **Squires RH (2003):** End stage liver disease in children. *Curr Treat options Gastroenterol.*, 4: 409-421.
 - **Stauber RE and Lackner C. (2007):** Non-invasive diagnosis of hepatic fibrosis in chronic hepatitis C. *World J. of Gastroenterology*: 13(32): 4287-4294.
 - **Stoller JK and Aboussouan LS.(2005):** Alpha-1-antitrypsin deficiency. *Lancet*:365:2225-2236.
 - **Suchy FJ (1996):** Chronic viral hepatitis in children. *Semin.Pediatr.gastroenterol.Nutr*; 2: 9-14.
 - **Suskind, DL and Muench MO. (2004):** Searching for common stem cells of the hepatic and hematopoietic systems in the human fetal liver: CD34+ cytokeratin 7/8+ cells express markers for stellate cells. *J. Hepatol.* 2004.40:261-268. View this article via: PubMed CrossRef
 - **Takeda T, Takahiro Y, Nakeryama Y and et al., (2006):** Usefulness of non invasive transient elastography for assessment of liver fibrosis stage in chronic hepatitis C. *world J Gastroenterol*; 28; 12(48): 7768-73.
 - **Takehara T, et al., (2004):** Hepatocyte-specific disruption of Bcl-xL leads to continuous hepatocyte apoptosis and liver fibrotic responses. *Gastro-enterology*. 2004.127:1189-1197.

- **Tanner JM.(1962):** Growth at adolescence, 2nd ed. Oxford, England, Black well. Scientific publications.
- **Tanner MS.(2004):** Disorders of copper metabolism. D Kelly -(ed.), Diseases of the Liver and Biliary System in Children, Blackwell Science, pp.243-258. \
- **Tarter RE, Hegedus AM, Van Thiel DH,et al., (1984):** Nonalcoholic cirrhosis associated with neuropsychological dysfunction in the absence of overt evidence of hepatic encephalopathy. *Gastroenterology*; 86:1421-1427.
- **Tawfeek N. (2005):** Recurrent limb pain in school children. M.S.C Thesis In Pediatrics. Benha Faculty of Medicine. 84.
- **Teare JP, Sherman D, Greenfield SM and et al., (1993):** Comparison of serum procollagen III peptide concentrations and PGA Index for assessment of hepatic fibrosis *Lancet*. 342:895-898.
- **Thomas P. and Ahsan M. (2001):** preventive strategies in chronic liver disease. *Journal of American Academy of family physicians*.
- **Thurman, RG. (1998):** Alcoholic liver injury involves activation of Kupffer cells by endotoxin. *Am. J. Physiol.* .275:G605-G611. View this article via: PubMed
- **Tran A, Hastier P, Barjoan EM and et al., (2000):** Noninvasive predication of severe fibrosis in patients with alcoholic liver fibrosis *Gastroenterol. Clin.Biol.*; 24: 626-630.

- **Varga J and Abraham D.(2007):** Systemic sclerosis : a prototypic multisystem fibrotic disorder. *J Clin Invest*; 117:557-67.
- **Verma S, Guuwan B, Mendler M, et al., (2004):** Factors predicting relapse and poor outcome in type I autoimmune hepatitis: role of cirrhosis development, patterns of transaminases during remission and plasma cell activity in the liver biopsy. *Am J Gastroenterol* 99:1510-1516.
- **Vinas O, et al., (2003):** Human hepatic stellate cells show features of antigen-presenting cells and stimulate lymphocyte proliferation. *Hepatology*. 38:919-929. View this article via: PubMed
- **Vozar I.(2005):** Serum laboratory markers for non-invasive diagnosis and monitoring of liver fibrogenesis in patients with chronic liver disease. *Bratisl Lek Listy*; 106(3): 123-126.
- **Vyzantiadis T, Theodoridou S, Giouleme O, et al.,(2003):** Serum concentrations of insulin-like growth factor-I in (IGF-I) in patients with liver cirrhosis. *Hepatogastroenterology* 50(51): 814-6.
- **Wai CT, Greenson JK, Fontana RJ and et al., (2003):** A simple non invasive Index can predict both significant fibrosis and cirrhosis in patients with Chronic hepatitis C. *Hepatology* 38:518-526.
- **Walsh KM, Fletcher A, McSween RN and et al., (2000):** Basement membrane peptides as markers of liver disease in chronic hepatitis CJ. *Hepatol.*; 32: 325.

- **Wanless IR and Shiota K. (2004):** The pathogenesis of nonalcoholic steatohepatitis and other fatty liver diseases: a four-step model including the role of lipid release and hepatic venular obstruction in the progression to cirrhosis. *Semin. Liver Dis.* 24:99-106. View this article via: PubMed CrossRef
- **Watnick S and Kirwin P. (2003):** The prevalence and treatment of depression among patients starting dialysis. *Am J V Kidney Dis*;41:105-10.
- **Weng LH, liu Y, chen LJ et al., (2009):** The etiology of liver damage imports cytokines transforming growth factor beta, and Interleukin –13 as driving force for fibrogenesis. *Hepatology* vol 50 issue 1 : 230:243.
- **Wessely S and Pariente C (2002):** Fatigue, depression and chronic hepatitis C infection. *Psychol Med*;32:1-10.
- **Wheeler MD, et al., (2001):** The role of Kupffer cell oxidant production in early ethanol-induced liver disease. *Free Radio. Biol Med.* 31:1544- 1549. View this article via: PubMed CrossRef
- **Whittington PF (2006):** Fetal and infantile hemochromatosis. *Hepatology* 43:654-660.
- **Whittington PF(2007):** Neonatal hemochromatosis: a congenital alloimmune hepatitis. *Semin Liver Dis*;27:243-250.
- **Wolf DC (2007):** Cirrhosis, pathophysiology of hepatic fibrosis.www.einedicme.com/med/topic3183.htm

- **Wong JB and Koff RS (2000):** Watchful waiting with periodic liver biopsy versus immediate empirical therapy for histologically mild chronic hepatitis C. A cost-effectiveness analysis. *Ann. Intern. Med.*; 133: 665-675.
- **Wu YL, Ye J, Zhang S, et al., (2004):** Clinical significance of serum IGF-1, IGF-II and IGFBP-3 in liver cirrhosis. *World J Gastroenterol.*, 10(18): 2740-3.
- **Yeh WC, Li PC, Jeng YM and et al., (2002)** Elastic modulus measurements of human liver and correlation with pathology. *Ultrasound Med Biol*; 28: 467-474
- **Yerushalmi B, Sokol RJ, Narkewicz MR, et al.,(2002):** Niemann-Pick disease type C in neonatal cholestasis at a North American Center. *J Pediatr Gastroenterol Nutr*;35:44-50.
- **Yonem O, Ozkayar N, and Balkanci F (2006):** Is congenital hepatic fibrosis a pure liver disease?. *Am J Gastroenterol*; 101(6): 1253-9.
- **Yoshida, T, et al., (2004):** SOCS1 is a suppressor of liver fibrosis and hepatitis-induced carcinogenesis. *J. Exp. Med.* 199:1701-1707. View this article via: PubMed CrossRef Streetz,
- **Younossi ZM, Boparai NO, Me Cormieck M, et al., (2001):** Assessment of utilities and health related quality of life in patients with chronic liver disease. *Am. J. Gastroenterol.*, 96(2): 579-583.

- **Youssini Zm, Boparai N and pricell A. (2001):** Health related quality of lives in chronic liver diseases, the impact of type and severity of disease. *J Gastroentrol* Jul 98 (7) 2199-205.
- **Yu C, et al., (2003):** Role of fibroblast growth factor type 1 and 2 in carbon tetrachloride-induced hepatic injury and fibrogenesis. *Am. J. Pathol.* 163:1653-1662. View this article via: PubMed
- **Zakaria N, Knisely A, Portmann B and et al., (2003):** Acute sickle cell hepatopathy represents a potential contraindication for percutaneous liver biopsy. *Blood*; 101: 101-103.
- **Zakim D and Boyer TD (1996):** Fibrosis: representative molecular elements, a basic concept and emerging targets for suppressive treatment (15): 465-498, Hepatic fibrosis and cirrhosis (16): 506-520 and Evaluation of liver function (28): 782-825. In: *Hepatology. A text-book of Liver Disease*, 3rd ed., Library of Congress, USA.
- **Zang S, Wliyl, Ye J. et al., (2004):** Clinical significance of IGF-1 and IGF-2 in liver cirrhosis world *J Gasterol* ; 10(18)2740-3.
- **Zhang BB, Min Cai W, Weng HL and et al., (2003):** Diagnostic value of platelet derived growth factor-B, transforming growth factor-1, matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in serum and peripheral blood mononuclear cells for hepatic fibrosis. *World J Gastroenterol*; 2490-2496.

- **Zietz B, lack G and Patch B (2003):** Dysfunction of the hypothalamic-pit- glandular axis in relation to child- pugh classification in males with alcoholic and viral related cirrhosis Eur J Gasteroentrol Hepatol 15 (5): 495-50.